Immune study in recessive dystrophic epidermolysis bullosa and stem cells
Part of Genetic & congenital, Skin clinical trials.
This study looks at the immune system in people with recessive dystrophic epidermolysis bullosa (RDEB) and tests how placental stem cells affect immune cells in the lab. It aims to understand the disease better and explore potential treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have a confirmed diagnosis of recessive dystrophic epidermolysis bullosa (intermediate, reversed, or generalized form)
- You are not taking anti-inflammatory or immune-suppressing medications within the last month
- You are willing to have a skin biopsy
- You do not have any other serious inflammatory disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the medical features and needs of people who have recessive dystrophic epidermolysis bullosa (RDEB). It may help doctors better understand the condition and plan better care.
This study follows people with dystrophic epidermolysis bullosa (DEB) who get scrapes on the surface of their eye (corneal abrasions). It collects information to better understand how often and how severely these eye injuries happen.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This trial tests a skin cell treatment called pz-cel (made from your own cells) for people with a severe skin condition called dystrophic epidermolysis bullosa (DEB). It aims to help heal wounds by applying specially grown skin sheets.
This trial tests a new skin graft made with your own cells that have been genetically modified to produce a missing protein (collagen 7). It's for people with RDEB, a severe blistering condition, and aims to see if the graft can heal wounds safely.
This study looks at long-term outcomes for people with recessive dystrophic epidermolysis bullosa (RDEB) who were previously treated with EB-101. It may help doctors understand how the treatment affects patients over time.
Hear when a new Epidermolysis Bullosa Dystrophica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.